Switzerland
KKR supports €220m refinancing of Selecta
Allianz acquired Selecta in 2007
Beechbrook holds €110m second close for Mezzanine II
Investor also announces new investments and recruits
Swiss venture investor B-to-V heads to Berlin
New location will see Swiss VC closer to start-up scene
PAI exits Nuance in trade sale to Dufry
Sale marks second exit from PAI's fifth European fund
LFPI holds first close of European Debt Fund
c25% of capital already raised has been invested
EQT sells Sportradar stake to itself
EQT originally invested in company July 2012
Novartis and Versant co-lead Anokion series-A
Anokion plans to use capital for clinical trials to start in 2017
Wellington in triple-deal close
Investments come from Wellington V Digital Fund
Tresorit raises $3m series-A
Latest round takes firm's total funding to $4.7m
Life Sciences Partners leads Sequana Medical series-C
Existing investors also contribute to CHF 23m round
Versant backs Crispr Therapeutics in €25m deal
VC firm's third investment in April
DACH: Growth capital value up as traditional buyouts suffer
Growth capital deals are proving more popular with businesses in the region
Versant Ventures injects CHF 11m into Piqur
VC firm also brings industry expertise to Piqur's board
Akina closes Euro Choice V on $372m
Firm is also fundraising for fund-of-funds Euro Choice Secondary
Nextech hires ex-Centrum Bank CEO as new partner
Lips also held roles at Falcon Private Bank and Goldman Sachs
Bravofly to pursue Zurich IPO
Listing expected to raise €80-110m
VC firms exit Activaero in trade sale
€130m proceeds to be split between cash and shares
Partners Group elects Peter Wuffli as chairman
Peter Wuffli, Partners Group
Boehringer Ingelheim leads early-stage round for Amal
Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds have invested in a seed-funding round for Swiss biotech start-up Amal Therapeutics.
Covagen extends series-B with Baxter investment
Swiss biotech Covagen has extended its CHF 42m series-B funding round, raised in December, to procure a further CHF 2.9m from Baxter Ventures.
Rosetta leads CHF 60m round for Novimmune
Life sciences-focused Rosetta Capital has led a CHF 60m ($66m) series-B funding round for Swiss biotech Novimmune.
Large-cap segment boosts DACH deal totals
Buyout activity was buoyed by a handful of large-cap deals in 2013. But is there hope for a brighter future further down the value scale? Amy King reports
Njord Partners backs GeoQuip with convertible loan
Njord Partners has provided Swiss oilfield services provider GeoQuip Marine with convertible loan financing.
Waterland appoints new German MD
Dutch firm Waterland Private Equity Investments has appointed Carsten Rahlfs as a principal and managing director of the German office.